Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00048126 · ClinicalTrials.gov registry record · Phase 2
A Study of Xeloda (Capecitabine) in Patients With Advanced and/or Metastatic Colorectal Cancer
A Phase 2 study, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 2
- Development phase
- 57
- Enrollment target
NCT00048126 is a Phase 2 study that has completed, run by Hoffmann-La Roche. The registered enrollment target is 57 participants.
The verdict
NCT00048126, a Phase 2 study, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 57 participants
- Enrollment target
Study Summary
This study will assess the efficacy and safety of continuous oral Xeloda administration in combination with intravenous irinotecan as a first-line treatment in patients with advanced and/or metastatic colorectal cancer. The anticipated time on study treatment is 3-12 months and the target sample size is \<100 individuals.
Interventions
- DRUG Irinotecan
- DRUG capecitabine [Xeloda]
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 57 participants |
| Start Date | 2001-07 |
| Est. Completion | 2005-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00048126
The ClinicalTrials.gov registry entry for NCT00048126 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 57 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Irinotecan is the first listed.
NCT00048126 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00048126 about?
NCT00048126 is a clinical study titled "A Study of Xeloda (Capecitabine) in Patients With Advanced and/or Metastatic Colorectal Cancer". This study will assess the efficacy and safety of continuous oral Xeloda administration in combination with intravenous irinotecan as a first-line treatment in patients with advanced and/or metastatic colorectal cancer. The anticipated time on study treatment is 3-12 months and the target sample siz...
What is the current status of trial NCT00048126?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 57 participants. The study started on 2001-07. Estimated completion is 2005-01.
What interventions are being tested in trial NCT00048126?
The interventions under investigation include: Irinotecan (DRUG), capecitabine [Xeloda] (DRUG).
Who is sponsoring clinical trial NCT00048126?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.